Cancer Research · 2015 · 37 citations · 42 references
MedicineCell BiologyOncologyMolecular OncologyOncogenesTumor ProgressionCancer Cell SignalingCancer Stem CellsCheckpoint Inhibitor TherapyGlioblastomaOncogenic Signaling PathwaysTargeted Cancer TherapyCancer Stem-like CellsGlioblastoma Stem CellsGlioblastoma Targeted TherapyGlioblastoma Therapeutic ResistancePolo-like Kinase FunctionPolo-like Kinase InhibitionPolo-like Kinase InhibitorsTherapy-resistant Cancer Stem Cells
The treatment of glioblastoma (GBM) remains challenging in part due to the presence of stem-like tumor-propagating cells that are resistant to standard therapies consisting of radiation and temozolomide. Among the novel and targeted agents under evaluation for the treatment of GBM are BRAF/MAPK inhibitors, but their effects on tumor-propagating cells are unclear. Here, we characterized the behaviors of CD133(+) tumor-propagating cells isolated from primary GBM cell lines. We show that CD133(+) cells exhibited decreased sensitivity to the antiproliferative effects of BRAF/MAPK inhibition compared to CD133(-) cells. Furthermore, CD133(+) cells exhibited an extended G2-M phase and increased polarized asymmetric cell divisions. At the molecular level, we observed that polo-like kinase (PLK) 1 activity was elevated in CD133(+) cells, prompting our investigation of BRAF/PLK1 combination treatment effects in an orthotopic GBM xenograft model. Combined inhibition of BRAF and PLK1 resulted in significantly greater antiproliferative and proapoptotic effects beyond those achieved by monotherapy (P < 0.05). We propose that PLK1 activity controls a polarity checkpoint and compensates for BRAF/MAPK inhibition in CD133(+) cells, suggesting the need for concurrent PLK1 inhibition to improve antitumor activity against a therapy-resistant cell compartment.
42
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
PubMed · 1997 · 66.6K citations
Roel G.W. Verhaak, Katherine A. Hoadley, Elizabeth Purdom et al. · Cancer Cell · 2010 · 7.7K citations · Full text
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Identification of human brain tumour initiating cells
Sheila K. Singh, Cynthia Hawkins, Ian D. Clarke et al. · Nature · 2004 · 7.4K citations
Medicine, Cancer Biology, Oncology +11